Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Advanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenAmerican Integrity is a newly public but seasoned Florida residential property insurer. The latest filings show 437,308 policies in force, $974.8 million of in-force premium, a 75.0% Q1 combined ratio and a reduced non-catastrophe quota share that lets AII kee
OpenSenmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
OpenAIG is now a focused global P&C underwriting and capital-return story. The latest filings show a 90.1 General Insurance combined ratio in 2025, an 87.3 combined ratio in Q1 2026, heavy buybacks, a smaller Corebridge stake and a live CEO transition.
OpenAIFU still has a large China insurance distribution platform, with 42,170 registered agents and 313 sales outlets, but the 2025 Form 20-F shows a severe revenue and asset-quality reset before a 2026 acquisition added dark tea inventory, heavy share issuance an
OpenAgroz has a real Malaysian CEA business and fast disclosed H1 2025 revenue growth, but AGRZ is a limited-disclosure microcap until it files FY2025 annual results, collects receivables and proves cash conversion.
OpenAGI Inc came public with Banco Agibank scale, 7.1 million active clients, a R$35.5 billion credit portfolio and post-IPO capital strength, but the thesis turns on INSS access, credit quality, funding spreads and founder-controlled governance.
OpenAllied still has HyperX Arena Las Vegas, Z-Tech mobile games, and a balance-sheet cushion, but the current thesis is about the late 10-K, Nasdaq delisting risk, reverse-split vote, Knighted settlement, and whether revenue can ever catch the cost base.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenABX is not a plain asset manager. It is a fast-growing life-settlement platform trying to convert policy origination, longevity data, and acquired asset managers into durable fee-related earnings.
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenACCESS Newswire has refocused around press release distribution, media monitoring, IR websites, events, and subscriptions after selling its Compliance business. The hook is improving ARR and retention; the risk is that the remaining company is still tiny, comp
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenAcco Group is not ACCO Brands. It is a Hong Kong and Singapore corporate-services microcap with US$4.9 million of FY2025 revenue, positive net income, an October 2025 Nasdaq IPO, and a January 2026 vote that approved a dual-class structure. The business is rea
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
Open